ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit Share Post Post navigation Previous PostAntengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCENext Post LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use